BIO-Europe: Centauri Therapeutics is planning to use antibody recruiting sugars that are linked to a targeting agent to treat infectious disease and cancer
CEO Jennifer Schneider describes how these "Alphamers" are designed to work and discusses the company's upcoming plans to enter the clinic.
Brought to you by